Diagosis of Breast Carcinoma: Characterization of Breast Lesions With CLEARPEMSONIC : Feasibility Study
|ClinicalTrials.gov Identifier: NCT01569321|
Recruitment Status : Terminated
First Posted : April 3, 2012
Last Update Posted : April 21, 2015
Breast cancer is the first cancer in women, the second etiology of death by cancer and the first cause for women between 35 and 55 years.
Diagnostic tools and large screening have been realized with positive impact in a recent review with 31% less likely to die of breast cancer over nearly 30 years compared to women who didn't get regular screening mammograms. Diagnostic tools and treatment also are improving continuously.
However, for some women, breast cancer diagnosis is difficult, in case of high density breast, breast modifications after surgery… In these cases, breast MRI is currently the best imaging tool, with high sensitivity about 90% but with a lower specificity about 60%, that lead to futile biopsies.
Recently, molecular imaging with PET-CT scan with 18FDG has permitted to widely modify cancer treatment.
However, PET-CT scan is not a good imaging tool for initial diagnostic of breast tumor because of a lack in spatial resolution about 8mm. So, researchers developed dedicated PET scan for breast, called Positron Emission Mammography. Our project is in this field of view and is named CLEARPEMSONIC.
First clinical studies with PEM showed very good performance of this imaging modality for initial evaluation of breast tumors. PEM performance is not affected by breast density, hormonal status. Spatial resolution is less than 3mm. PEM seems complementary with MRI, adding a better specificity value.
In the field of CERIMED, ClearPemSonic Project aims to evaluate an new imaging tool which combined PEM scan and ultrasonography.
Technologic evaluation was made. Now a feasibility study is the first step for clinical applications.
The main objective of this project is to confirm the feasibility of PEM scan with the ClearPEmSonic.
Secondary objectives are to compare results with other conventional imaging modalities and MRI.
The gold standard will be histology of the breast tumor.
|Condition or disease||Intervention/treatment||Phase|
|Breast Carcinoma||Device: MRI Device: PET-CT scan Device: PEM scan with ClearPemSonic||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Diagosis of Breast Carcinoma: Characterization of Breast Lesions With CLEARPEMSONIC : Feasibility Study|
|Study Start Date :||March 2012|
|Actual Primary Completion Date :||March 2013|
|Actual Study Completion Date :||March 2013|
|Experimental: Breast cancer||Device: MRI Device: PET-CT scan Device: PEM scan with ClearPemSonic|
- MEASURE the Positron Emission Mammography (PEM) [ Time Frame: 12 months ]the feasibility of PEM scan with the ClearPEmSonic
- MEASURE the other conventional imaging modalities and MRI. [ Time Frame: 12 MONTHS ]to compare results with the different device
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01569321
|Assistance Publique Hopitaux de Marseille|
|Marseille, France, 13354|
|Study Director:||BERNARD BELAIGUES||Assistance Publique hôpitaux de Marseille|